Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer?. Issue 1 (10th August 2016)

• Record Type: Journal Article
• Authors: Ratajczak, Mariusz Z.; Suszynska, Malwina; Kucia, Magda
• Is Part Of: Clinical and translational medicine. Volume 5:Issue 1(2016)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2016-08-10
• Subjects: Cancer metastasis -- Pro‐metastatic microenvironment -- SDF‐1 -- S1P -- C1P -- HGF; Clinical medicine -- Periodicals; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 616.027
• DOI: 10.1186/s40169-016-0113-6
• Languages: English
• ISSNs: 2001-1326

Abstract

Abstract: The major problem with cancer progression and anti‐cancer therapy is the inherent ability of cancer cells to migrate and establish distant metastases. This ability to metastasize correlates with the presence in a growing tumor of cells with a more malignant phenotype, which express certain cancer stem cell markers. The propensity of malignant cells to migrate and their resistance to radio‐chemotherapy somewhat mimics the properties of normal developmentally early stem cells that migrate during organogenesis in the developing embryo. In the past, several factors, including cell migration‐promoting cytokines, chemokines, growth factors, bioactive lipids, extracellular nucleotides, and even H + ions, were found to influence the metastasis of cancer cells. This plethora of pro‐migratory factors demonstrates the existence of significant redundancy in the chemoattractants for cancer cells. In spite of this obvious fact, significant research effort has been dedicated to demonstrating the crucial involvement of particular pro‐metastatic factor–receptor axes and the development of new drugs targeting one receptor or one chemoattractant. Based on our own experience working with a model of metastatic rhabdomyosarcoma as well as the work of others, in this review we conclude that targeting a single receptor–ligand pro‐metastatic axis will not effectively prevent metastasis and that we should seek other more effective therapeutic options.